All In Biotech

Drug Trial Radar · NCT07172971

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

duCHennE caRdiomyopathy mItigation Sglt2 inHibitor

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Aug 1, 2027

Study completion Feb 1, 2028

Sponsor

Lead sponsor
Vanderbilt University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Sep 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Male only, from 8 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients. Empagliflozin is currently used off-label in this population due to the mortality benefits seen in adult cardiomyopathy and heart failure. Investigators will perform PK studies in DMD patients of various ages and weights to better understand the PK profile (absorption, distribution, metabolism, excretion) and dosing to better treat Duchenne cardiomyopathy.

Conditions

  • Duchenne Muscular Dystrophy (DMD)

Interventions

  • SGLT-2 inhibitorDrug

    SGLT-2 inhibitor will be given once daily by mouth

  • SGLT2 inhibitorDrug

    SGLT-2 inhibitor will be given once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Medication doseTime frame: From enrollment to 12 month analysis

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.